Liver cirrhosis is a chronic liver disease characterized by permanent scarring that replaces healthy tissue and progressively impairs liver function. As fibrosis advances, patients can develop portal hypertension, decompensation, and eventual liver failure.
New noninvasive biomarkers are advancing early detection of fibrosis. A FAP-Index blood test reduces uncertain liver fibrosis results by up to 70%, a urine-based molecular imaging test detects kidney fibrosis with 84% sensitivity and 94% specificity, and liver MRE can track Gaucher disease severity over time.
In the Philippines, an estimated 7.3 million adults live with chronic hepatitis B, far above regional averages. Experts warn that complex treatment guidelines may hinder front-line clinicians from initiating care, while Thailand’s success with vaccination shows a path to elimination. Expanding screening and simplifying treatment are critical steps.
A study from the University of Osaka identified the integrin αV–YAP–CTGF pathway linking chronic liver congestion to fibrosis. The findings point to a potential therapeutic target in congestion-related liver disease.
A major meta-analysis of 19 randomized trials involving 123,940 participants found that only six side effects are actually caused by statins, challenging long-standing concerns about the drugs' safety profile.
New studies show SGLT2 inhibitors and GLP-1 receptor agonists reduce risks of kidney failure, cardiovascular events, and liver complications in patients with type 2 diabetes, with particularly strong benefits in those with cirrhosis.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07777705 |
Application of Different Scores in Predicting Outcomes of Cirrhotic Patients Awaiting Liver Transplantation |
NOT_YET_RECRUITING | |
| NCT07764835 |
Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC) |
NOT_YET_RECRUITING | |
| NCT07755059 |
Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis |
NOT_YET_RECRUITING | NA |
| NCT07750587 |
Predicting Response and Exposure Changes in Cirrhosis for Effectiveness |
NOT_YET_RECRUITING | NA |
| NCT07734896 |
Evaluating Novel Scoring Systems to Predict Outcomes in Acute-on-Chronic Liver Failure |
NOT_YET_RECRUITING | |
| NCT07726693 |
Apixaban to Prevent Decompensation of Early Liver Cirrhosis Trial |
NOT_YET_RECRUITING | PHASE3 |
| NCT07716384 |
Wearable Patch Ultrasound Probe for Diagnosis of Liver Stiffness |
NOT_YET_RECRUITING | |
| NCT07701031 |
Assessing EUS and Percutaneous Untargeted Liver Biopsy Quality |
COMPLETED | |
| NCT07681089 |
A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia |
RECRUITING | PHASE2 |
| NCT07658794 |
Intraoperative Assessment of Microcirculatory Function Using Vascular Occlusion Test During Liver Transplantation |
NOT_YET_RECRUITING |
